Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes

Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes. Heart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE inhibitor enalapril -   Magnitude of benefit was twice as high in a sub group of patients with HF and diabetes -   Up to 40% of HF patients have diabetes, which is associated with greater risk of developing chronic kidney disease leading to poorer cardiovascular outcomes , , -   In addition to the established benefits on mortality and HF hospitalizations, Entresto treatment also helps to preserve kidney function, especially in diabetic patients - Novartis today announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, demonstrating that treatment with Entresto (sacubitril/valsartan) helped to preserve kidney function, as assessed by estimated glomerular filtration rate (eGFR), in patients with heart failure with reduced ejection fraction (HFrEF). HFrEF patients treated with Entresto had a slower rate of decline in eGFR than those treated with ACE inhibitor enalapril. In a sub group of patients who had both HFrEF and diabetes, the magnitude of benefit was twice as high. The findings of the analysis are published today in The Lancet Diabetes & Endocrinology . "These results suggest that in addition to the established benefits on heart failure, Entresto treatment also helps to preserve kidney function.